



**University of  
Zurich**<sup>UZH</sup>

**Zurich Open Repository and  
Archive**

University of Zurich  
University Library  
Strickhofstrasse 39  
CH-8057 Zurich  
[www.zora.uzh.ch](http://www.zora.uzh.ch)

---

Year: 2013

---

## **Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies**

Gobbi, C ; Zecca, C ; Linnebank, M ; Müller, S ; You, X ; Meier, R ; Borter, E ; Traber, M

**Abstract:** BACKGROUND: There is a scarcity of reports comparing efficacy and tolerability of the multiple sclerosis (MS) disease-modifying therapies [DMTs; intramuscular interferon- 1a (IM IFN -1a), subcutaneous (SC) IFN -1a, SC IFN -1b, SC glatiramer acetate (GA)] in a real-world setting. **METHODS:** This multicenter, non-interventional, retrospective cohort study analyzed data from 546 patients with clinically isolated or relapsing-remitting MS constantly treated with one DMT for 2 years. Annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) scores, and DMT tolerability were assessed. **RESULTS:** Demographic data were comparable across DMTs. There were no significant differences between DMT groups in ARR during study year 1 ( $p = 0.277$ ) or study year 2 ( $p = 0.670$ ), or in EDSS change between years 1 and 2 ( $p = 0.624$ ). Adverse events were frequent (39-56%) in all groups. Flu-like symptoms were less frequent with GA treatment (2.3% vs. IM IFN -1a, 46.7%; SC IFN -1a, 39.8%; SC IFN -1b, 25.8%;  $p < 0.05$ ). Injection site reactions were less often reported with IM IFN -1a (10.5% vs. SC IFN -1a, 33.9%; SC IFN -1b, 38.3%; GA, 26.1%;  $p < 0.05$ ). **CONCLUSIONS:** All DMTs showed comparable effects on MS relapse rate and EDSS change, with IM IFN -1a and GA being more tolerable with respect to injection site reactions and flu-like symptoms, respectively.

DOI: <https://doi.org/10.1159/000346761>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-86070>

Journal Article

Published Version

Originally published at:

Gobbi, C; Zecca, C; Linnebank, M; Müller, S; You, X; Meier, R; Borter, E; Traber, M (2013). Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies. *European Neurology*, 70(1-2):35-41.

DOI: <https://doi.org/10.1159/000346761>

# Swiss Analysis of Multiple Sclerosis: A Multicenter, Non-Interventional, Retrospective Cohort Study of Disease-Modifying Therapies

Claudio Gobbi<sup>a</sup> Chiara Zecca<sup>a</sup> Michael Linnebank<sup>b</sup> Stefanie Müller<sup>c</sup>  
Xiaojun You<sup>e</sup> Rosetta Meier<sup>d</sup> Emanuela Borter<sup>d</sup> Martin Traber<sup>d</sup>

<sup>a</sup>Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Ospedale Regionale di Lugano, Lugano,

<sup>b</sup>University Hospital Zurich, Zurich, <sup>c</sup>Cantonal Hospital St. Gallen, St. Gallen, and <sup>d</sup>Biogen-Dompé AG, Zug, Switzerland; <sup>e</sup>Biogen Idec Inc., Weston, Mass., USA

## Key Words

Multiple sclerosis · Disease-modifying therapies · Swiss Analysis of Multiple Sclerosis study · Efficacy · Safety

## Abstract

**Background:** There is a scarcity of reports comparing efficacy and tolerability of the multiple sclerosis (MS) disease-modifying therapies [DMTs; intramuscular interferon- $\beta$ 1a (IM IFN $\beta$ -1a), subcutaneous (SC) IFN $\beta$ -1a, SC IFN $\beta$ -1b, SC glatiramer acetate (GA)] in a real-world setting. **Methods:** This multicenter, non-interventional, retrospective cohort study analyzed data from 546 patients with clinically isolated or relapsing-remitting MS constantly treated with one DMT for 2 years. Annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) scores, and DMT tolerability were assessed. **Results:** Demographic data were comparable across DMTs. There were no significant differences between DMT groups in ARR during study year 1 ( $p = 0.277$ ) or study year 2 ( $p = 0.670$ ), or in EDSS change between years 1 and 2 ( $p = 0.624$ ). Adverse events were frequent (39–56%) in all groups. Flu-like symptoms were less frequent with GA treatment (2.3% vs. IM IFN $\beta$ -1a, 46.7%; SC IFN $\beta$ -1a, 39.8%; SC IFN $\beta$ -1b, 25.8%;  $p < 0.05$ ). Injection site reactions were less often reported with IM IFN $\beta$ -1a (10.5% vs. SC IFN $\beta$ -1a, 33.9%; SC IFN $\beta$ -1b, 38.3%; GA, 26.1%;  $p < 0.05$ ). **Conclusions:** All DMTs

showed comparable effects on MS relapse rate and EDSS change, with IM IFN $\beta$ -1a and GA being more tolerable with respect to injection site reactions and flu-like symptoms, respectively.

Copyright © 2013 S. Karger AG, Basel

## Introduction

The efficacy and tolerability of injectable interferon- $\beta$  (IFN $\beta$ ) and glatiramer acetate (GA) as first-line disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) have been validated in pivotal phase 3 trials [1–5]. Across several clinical studies, IFN $\beta$  and GA reduced the average patient MS relapse rate by approximately one third [1–4] and decreased magnetic resonance imaging (MRI) T2-weighted brain lesion volume and the number of gadolinium-enhancing brain lesions compared with placebo [5, 6]. However, the comparative efficacy of these immunomodulatory therapies remained uncertain, since it cannot be derived from past trial results because of differences in study methodology, outcome criteria, and patient populations among trials.

R.M. is a former employee of Biogen-Dompé AG.


Previous DMT comparative studies have typically evaluated only 2 of the four commercially available injectable therapies [7–10]. Two large, pharmaceutical industry-sponsored head-to-head trials showed that self-injectable subcutaneous (SC) IFN $\beta$  was not superior to GA with regard to clinical efficacy outcomes over 2 years [7, 8]. There have also been 2 reported head-to-head trials that showed superior efficacy for SC IFN $\beta$  compared with intramuscular (IM) IFN $\beta$  in lengthening the time to the first clinical relapse on study [9, 10]. However, study populations in phase 2 and 3 clinical trials may not represent the general population in which the studied drugs will be used after approval, and it is therefore well recognized that clinical trial results may only be partially reproducible in general clinical practice.

Several open-label, postmarketing, observational studies have reported similar efficacy for the three different IFN $\beta$  preparations [11–19], but only a few have compared these DMTs and GA [20, 21]. There is only one report in the literature comparing the effects of all four different immunomodulatory therapies on MS disease progression in patients with relapsing-remitting MS (RRMS); however, the study groups were quite imbalanced, and the reported differences in hazard ratios between the DMTs were attributed to selection bias [22]. So far, multicenter clinical data comparing the use of all four injectable DMTs in patients with clinically isolated syndrome (CIS) or RRMS have not previously been reported. We present the results of a retrospective study comparing efficacy, safety, and tolerability of the three IFN $\beta$  preparations and GA in patients with CIS or RRMS in a real-world setting.

## Methods

### Patients

The Swiss Analysis of Multiple Sclerosis (SAME) study was a multicenter, non-interventional, retrospective cohort study that included patients constantly treated for at least 2 years with either one of the IFN $\beta$  or GA at 30 centers in Switzerland. The inclusion criteria were age between 18 and 65 years at first visit, a diagnosis of either CIS or RRMS according to the 2005 revised McDonald criteria [23], and treatment with the same DMT for the last 2 years. Availability of patient demographic information, medical history, and results of neurological examinations were required for inclusion in the study. All patients who met these criteria from June to October 2010 were included. Eligible patients had received continuous treatment with one of four first-line DMTs (IM IFN $\beta$ -1a 30  $\mu$ g, Avonex<sup>®</sup>; SC IFN $\beta$ -1a 22/44  $\mu$ g, Rebif<sup>®</sup>; SC IFN $\beta$ -1b 250  $\mu$ g, Betaferon<sup>®</sup>, or GA 20 mg, Copaxone<sup>®</sup>) at standard doses for at least 2 years (i.e. the study period). Use of any MS treatment for any duration was allowed prior to the study period. Study exclu-



**Fig. 1.** SAME study timeline.

sion criteria were DMT treatment <2 years, interruption in DMT therapy during the study period, therapy that did not include a first-line DMT, or the occurrence of an MS relapse during the 4 weeks immediately prior to enrollment in SAME. All patients provided informed consent, and the study was approved by each study site's institutional review board or clinical research ethics committee.

### Study Design

The SAME study was a multicenter, non-interventional, retrospective cohort study that analyzed data from patients treated at one of 30 MS centers in Switzerland with an IFN $\beta$  or GA for at least 2 years. The study period was defined as 24 months of continuous use of the same DMT and was divided into the two time intervals of the first 12 months (year 1) and the second 12 months (year 2) of the study period (fig. 1).

For each patient, participating investigators completed a case report form that requested information on patient demographic and clinical data, including date of birth, gender, date of CIS or RRMS diagnosis, preparation and dose of the DMT, first treatment after MS diagnosis prior to the start of the SAME study period (i.e. 'initial therapy'), number of relapses, and Expanded Disability Status Scale (EDSS) scores. MRI scans were performed according to clinical need and in only a limited number of patients (27%, data not shown). Participating study sites entered data using a secure, web-based tool created for the study that ensured the quality of the data collection and also allowed for consolidated monitoring.

The primary study end point was the annualized relapse rate for years 1 and 2 (categorized as 0, 1, 2, or  $\geq 3$ ). A relapse was defined, according to widely accepted international diagnostic and therapeutic guidelines [23], as newly developed neurological symptoms or reactivation of preexisting neurological deficits for a minimum of 24 h in the absence of an increase in body temperature or infections, or as symptoms occurring at least 30 days after the preceding episode. The secondary end point was change in patient EDSS score from year 1 to year 2. In addition, treatment-associated adverse events (AEs) during SAME study years 1 and 2 were collected in all patients [categorized into flu-like symptoms, injection site reactions (redness, inflammation, necrosis, and lipodatrophy), and other].

**Table 1.** Patient demographic and clinical characteristics

	All DMTs	DMT				p value	Switch vs. no switch		p value
		IM IFN $\beta$ -1a	SC IFN $\beta$ -1a	SC IFN $\beta$ -1b	GA		DMT as first therapy	switch to DMT	
Patients	546 (100)	105 (19)	186 (35)	167 (30)	88 (16)	–	458 (84)	88 (16)	–
Males	164 (30)	24 (23)	61 (33)	52 (31)	27 (31)	0.339 <sup>a</sup>	139 (30)	25 (28)	0.716 <sup>a</sup>
Age, years	44.0 $\pm$ 10.5	43.6 $\pm$ 11.5	43.6 $\pm$ 10.3	45.0 $\pm$ 10.4	43.4 $\pm$ 9.9	0.530 <sup>b</sup>	43.9 $\pm$ 10.5	44.3 $\pm$ 10.4	0.772 <sup>b</sup>
Diagnosis									
RRMS	492 (90)	92 (88)	175 (94)	145 (87)	80 (91)	0.106 <sup>a</sup>	410 (89)	82 (79)	0.292 <sup>a</sup>
CIS	54 (10)	13 (12)	11 (6)	22 (13)	8 (9)		48 (11)	6 (7)	
Median disease duration, years									
RRMS	7.7 (4.8–12.8)	6.0 (3.7–11.3) <sup>c</sup>	7.5 (5.7–11.7)	9.5 (4.8–15.2) <sup>c</sup>	7.6 (4.3–12.8)	0.007 <sup>d</sup>	7.3 (4.4–11.8)	11.7 (6.9–15.5)	<0.001 <sup>e</sup>
CIS	4.3 (3.0–7.4)	4.5 (3.0–6.8)	5.5 (3.7–7.3)	3.4 (2.8–4.8)	8.1 (3.4–13.0)	0.244 <sup>d</sup>	4.1 (2.9–6.8)	6.7 (3.1–11.7)	0.459 <sup>e</sup>
Number of relapses									
Year 1									
0	438 (80)	83 (79)	142 (76)	141 (84)	72 (82)	0.277 <sup>a</sup>	371 (81)	67 (76)	0.294 <sup>a</sup>
$\geq 1^f$	108 (20)	22 (21)	44 (24)	26 (16)	16 (18)		87 (19)	21 (24)	
Year 2									
0	413 (76)	79 (75)	136 (73)	129 (77)	69 (78)	0.670 <sup>a</sup>	355 (77)	58 (66)	0.066 <sup>a</sup>
1	105 (19)	21 (20)	38 (20)	33 (20)	13 (15)		81 (18)	24 (27)	
$\geq 2^g$	28 (5)	5 (5)	12 (7)	5 (3)	6 (7)		22 (5)	6 (7)	
Median EDSS									
Year 1	2 (1.5–3.0)	2 (1.5–3.0)	2.25 (1.5–3.5)	2 (1.5–3.5)	2.5 (1.5–3.0)	0.196 <sup>d</sup>	2 (1.5–3)	2.5 (1.5–3.5)	0.019 <sup>e</sup>
Year 2	2 (1.5–3.5)	2 (1.0–3.0)	2 (1.5–3.5)	2 (1.5–4.0)	2.5 (1.3–3.0)	0.167 <sup>d</sup>	2 (1.5–3.5)	2.5 (2–4)	0.009 <sup>e</sup>

Values for age are expressed as mean  $\pm$  SD. Figures in parentheses indicate percentages or interquartile range. <sup>a</sup>  $\chi^2$  test. <sup>b</sup> Analysis of variance. <sup>c</sup> Post-hoc comparison, adjusted  $p < 0.05$  for pairwise comparison. <sup>d</sup> Kruskal-Wallis one-way analysis of variance. <sup>e</sup> Mann-Whitney U test. <sup>f</sup> Only 8 patients had two or more relapses during year 1. <sup>g</sup> Only 3 patients had three or more relapses during year 2.

### Statistical Analyses



The planned analysis compared the number of relapses, EDSS score, change in EDSS score, and frequency of AEs between treatment groups. In addition, patients who had switched to DMT before the study (the 'switch' group) were compared with those for whom DMT was the first treatment (the 'no-switch' group). Because of the non-normal distribution of the outcomes, comparisons used nonparametric tests (U tests, Kruskal-Wallis one-way analysis of variance, and  $\chi^2$  tests, as appropriate). Bonferroni post hoc tests were conducted for comparisons that showed overall significant differences. Results were considered significant at  $p < 0.05$ .

### Results



A total of 546 subjects were enrolled in SAME. Patient demographic were similar across all four treatment groups (table 1). The overall mean age at enrollment ( $\pm$  standard deviation) was  $44 \pm 10.5$  years, and the majority of patients (70%) were women. Ninety percent of patients presented with RRMS. Disease duration was largely comparable across treatment groups for CIS pa-

tients, though RRMS patients treated with SC IFN $\beta$ -1b had a longer disease duration than patients treated with IM IFN $\beta$ -1a ( $p < 0.05$ , post hoc test; table 1). There were no significant differences between groups in relapse rate (fig. 2) or EDSS score during years 1 or 2 (fig. 3 and table 1). In addition, change in EDSS score from year 1 to year 2 did not differ significantly between treatment groups ( $p = 0.624$ , Kruskal-Wallis one-way analysis of variance).

A total of 88 patients (22 on IM IFN $\beta$ -1a, 16 on SC IFN $\beta$ -1a, 8 on SC IFN $\beta$ -1b, and 42 on GA) had used different DMTs prior to SAME. When patients receiving a DMT as their first drug (458 patients) and those receiving a DMT as their second drug (88 patients) were compared, the 2 groups did not differ in age, gender, or proportion of patients with RRMS or CIS (table 1). Patients who had switched to a DMT had a longer disease duration and higher EDSS scores both during year 1 and 2 than those who had originally received a DMT. The EDSS change between year 1 and 2 was, however, comparable between groups ( $p = 0.472$ , Mann-Whitney U test).



**Fig. 2.** Number of relapses during SAME. **a** Year 1. **b** Year 2.



**Fig. 3.** Median EDSS score during SAME. **a** Year 1. **b** Year 2.

**Table 2.** AEs during 2-year DMT in MS

AEs	DMT					p value <sup>a</sup>
	IM IFNβ-1a	SC IFNβ-1a	SC IFNβ-1b	GA	all DMTs	
Any AEs	59 (56.2)	102 (54.8)	89 (53.3)	34 (38.6)	284 (52.0)	0.052
Flu-like symptoms	49 (46.7)	74 (39.8)	43 (25.8)	2 (2.3)	168 (30.8)	<0.001
Injection-site reactions <sup>b</sup>	11 (10.5)	63 (33.9)	64 (38.3)	23 (26.1)	161 (29.5)	<0.001
Redness	10 (9.5)	56 (30.1)	59 (35.3)	16 (18.2)	141 (25.8)	
Inflammation	4 (3.8)	19 (10.2)	19 (11.4)	3 (3.4)	45 (8.2)	
Necrosis	0	4 (2.2)	8 (4.8)	1 (1.1)	13 (2.4)	
Lipoatrophy	0	10 (5.4)	11 (6.6)	7 (8.0)	28 (5.1)	
Other	12 (11.4)	18 (9.7)	10 (6.0)	13 (14.8)	53 (9.7)	0.135

<sup>a</sup> Treatment differences in AEs were analyzed using  $\chi^2$  tests, with significance accepted when  $p < 0.05$ . <sup>b</sup> Individual patients recorded one or more types of injection site reactions. Percentages are given in parentheses.



Overall, patient reports of treatment-related AEs did not differ significantly ( $p = 0.052$ ) between treatment groups, although some group differences in specific AEs were evident (table 2). The predominant AEs were flu-like symptoms and local injection site reactions. Reports of flu-like symptoms were significantly less frequent with GA compared to all other DMTs and SC IFN $\beta$ -1b compared to IM IFN $\beta$ -1a and SC IFN $\beta$ -1a (adjusted  $p < 0.05$  for all post hoc comparisons). On the other hand, patients on IM IFN $\beta$ -1a experienced significantly fewer injection site reactions ( $p < 0.001$ ) than patients on the other three DMTs, with redness and inflammation being the most commonly reported injection site reactions.

## Discussion

This multicenter, retrospective, observational study in a selected real-world MS population of nearly 550 patients demonstrated that the four first-line DMTs for the treatment of MS had a similar impact on annualized relapse rate and disability progression (as indicated by change in EDSS score) during the 2-year study. There were no major differences in AEs between patients receiving the different DMTs, although the prevalence of injection site reactions and flu-like symptoms seemed to be lower with IM IFN $\beta$ -1a and GA, respectively. To our knowledge, this is the first study that simultaneously compared the efficacy and side effects of these four first-line DMTs in a large cohort of patients affected by RRMS and CIS in a multicenter real-world setting. Our study population of 546 patients from 30 Swiss centers represents approximately 10% of the estimated Swiss MS population. The current study evaluated an MS patient cohort during a 2-year period of uninterrupted first-line MS therapy. Given that the majority (87%) of patients in the SAME study had been on the same DMT for many years, we suggest that these patients represent a selected, stable, real-world MS patient population. In addition, we conducted a separate analysis that stratified the group into patients receiving the DMT as first- or second-line treatment and showed that the latter group, as expected, was more severely affected in terms of disability. However, relapse rate and disability progression over 2 years did not differ between the 2 groups. All of the AEs reported by patients were expected, and they occurred at similar frequencies as in previous reports [24].

These results are in line with other short- and long-term real-world postmarketing studies [11–21]. Never-

theless, 2 previous head-to-head trials, EVIDENCE [9] and INCOMIN [10], showed superior efficacy for SC IFN $\beta$  compared with IM IFN $\beta$  in terms of time to the first clinical MS relapse on study. However, differences between treatment groups in patient baseline characteristics, variation in MS therapies prior to study initiation, absence of a placebo comparator group, regression to the mean, and possible selection bias may limit the utility of those data.

The study has several limitations that should be taken into account when interpreting its results. The first and most important limitation is represented by the retrospective nonrandomized study design. In general, randomized studies have a better research design, since possible biases cannot be fully overcome by statistical methods in open-label, non-randomized studies [25]. However, it is not always feasible to conduct randomized trials, and alternative study designs will inevitably need to be utilized. Benson and Hartz [26] reported that the estimates of treatment effects from observational studies and randomized controlled trials are similar. The value of observational studies should therefore not be underestimated since phase 4 studies and retrospective chart reviews can also reveal important differences among drugs in the same class that were not detected in controlled phase 2 or 3 clinical trials [17]. In addition, in Switzerland all DMTs are approved first-line treatments for MS patients. The official administrative recommendations do not differ among DMTs, and there are no guidelines that preferentially recommend one specific DMT for these patients. Therefore, we can tentatively assume that all DMTs in our study were prescribed with the same a priori probability in MS patients.

Second, patients on stable DMT treatment for at least 2 years in the SAME study most likely represent long-term responders to DMTs or patients with low disease activity; they may differ from the general population of MS patients. As a consequence, we cannot generalize our results to the entire MS population. Finally, the absence of a systematic MRI follow-up precludes from identifying differences in subclinical disease activity, which is more sensitive than clinical parameters only.

To conclude, in a real-world setting in a selected MS patient population the four injectable DMTs showed more similarities than differences in the efficacy and safety of the treatment of MS during a 2-year study period.

## Acknowledgments

The authors thank the many people with MS who participated in this study and gratefully acknowledge the support of the staff at the clinical study sites. We also thank Stephany Fulda for help in manuscript preparation and statistical analysis. Medical writing assistance was provided by Christopher Barnes, and editorial support was provided by Joshua Safran, both of Infusion Communications. Their work was funded by Biogen Idec Inc. This study was supported by Biogen-Dompé AG.

## Disclosure Statement

Claudio Gobbi has received honoraria from Bayer Schering, Biogen-Dompé, Merck Serono, Novartis, and Teva. Chiara Zecca has received honoraria from Bayer Schering, Merck Serono, Novartis, and Teva. Michael Linnebank has received grants or honoraria from Abbott, Bayer, Biogen-Dompé, Desitin, Merck, Novartis, Pfizer, Sanofi and Teva. Stefanie Müller has received honoraria, travel grants, research grants, and personal compensation from Bayer Healthcare, Biogen-Dompé, Merck Serono, Novartis, sanofi-aventis, and Teva. Xiaojun You is an employee of Biogen Idec Inc. Emanuela Borter and Martin Traber are employees of Biogen-Dompé AG. Rosetta Meier is a former employee of Biogen-Idec AG.

## References

- 1 IFNB Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. *Neurology* 1993;43: 655–661.
- 2 Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownschidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pulicino PM, Scherokman BJ, Whitham RH: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). *Ann Neurol* 1996;39:285–294.
- 3 Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. *Neurology* 1995;45: 1268–1276.
- 4 PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. *Lancet* 1998;352:1498–1504.
- 5 Paty DW, Li DK: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. *Neurology* 1993;43:662–667.
- 6 Comi G, Filippi M, Wolinsky JS: European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging – measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. *Ann Neurol* 2001;49: 290–297.
- 7 O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T, BEYOND Study Group, O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Harung HP, Kappos L, Jeffery D, Comi G: 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. *Lancet Neurol* 2009;8:889–897.
- 8 Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitendhaag BM, REGARD study Group: Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REBif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. *Lancet Neurol* 2008;7:903–914.
- 9 Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B, EVIDENCE (Evidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group, University of British Columbia MS/MRI Research Group: Randomized, comparative study of interferon  $\beta$ -1a treatment regimens in MS: the EVIDENCE Trial. *Neurology* 2002;59:1496–506.
- 10 Durelli L, Verdun E, Barbero P, Ricci A, Zhong JJ, Ferrero B, Clerico M, Pipieri A, Verdun E, Giordano L, Durelli L, INCOMIN Trial Study Group: Every-other-day interferon beta-1a versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). *Lancet* 2002;359:1453–1460.
- 11 Milanese C, La Mantia L, Palumbo R, Martinelli V, Murialdo A, Zaffaroni M, Caputo D, Capra R, Bergamaschi R, North Italy Multiple Sclerosis Group: A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. *J Neurol Neurosurg Psychiatry* 2003;74:1689–1692.
- 12 Miralles AA, Fuentes B, Barreiro P, Diez-Tejedor E: Comparative clinical efficacy analysis between interferon beta 1-b and interferon beta 1-a (abstract). *J Neurol* 2000; 247:III139.
- 13 Öztekin N, Öztekin MF: An open-label trial comparing the effects of IFN $\beta$ -1a (Rebif), (Avonex), and IFN $\beta$ -1b (Betaferon) on the relapse rate, lesion load on MRI and disease progression in patients with relapsing-remitting multiple sclerosis: results of 24 months of therapy (abstract P312). *Mult Scler* 2001; 7(suppl 1):S96.
- 14 Pakdaman H: Response to beta-interferon in Iranian multiple sclerosis patients (abstract P146). *Mult Scler* 2001;7(suppl 1):S54.
- 15 Río J, Tintoré M, Nos C, Téllez N, Galán I, Montalban X: Interferon beta in relapsing-remitting multiple sclerosis: an eight years experience in a specialist multiple sclerosis centre. *J Neurol* 2005;252:795–800.
- 16 Seijo-Martinez M, Amigo MC, Arias M, et al: Experience of interferon beta (INF- $\beta$ ) treatment in relapsing-remitting (RR) and secondary progressive (SP) multiple sclerosis (MS) in Galicia (Spain) (abstract P144). *Mult Scler* 2001;7(suppl 1):S54.
- 17 Trojano M, Liguori M, Paolicelli D, Zimatore GB, De Robertis F, Avolio C, Giuliani F, Fuianni A, Livrea P, Southern Italy MS Group: Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. *Mult Scler* 2003;9: 451–457.
- 18 Patti F, Pappalardo A, Florio C, Politi G, Fiorilla T, Reggio E, Reggio A: Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study. *Acta Neurol Scand* 2006;113:241–247.

- 19 Limmroth V, Malessa R, Zettl UK, Koehler J, Japp G, Haller P, Elias W, Obhof W, Viehöver A, Meier U, Brosig A, Hasford J, Putzki N, Kalski G, Wernsdörfer C, QUASIMS Study Group: Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. *J Neurol* 2007;254:67–77.
- 20 Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP: A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. *Mult Scler* 2001;7:349–353.
- 21 Haas J, Firzlaß M: Twenty-four-month comparison of immunomodulatory treatments – a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). *Eur J Neurol* 2005;12:425–431.
- 22 Sørensen PS, Koch-Henriksen N, Ravnborg M, Frederiksen JL, Jensen K, Heltberg A, Schaldemose H, Deth S, Kristensen O, Worm M, Stenager E, Hansen HJ, Sivertsen B, Tørring J, Danish Multiple Sclerosis Study Group: Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey. *Mult Scler* 2006;12:253–264.
- 23 Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS: Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. *Ann Neurol* 2005;58:840–846.
- 24 Derwenskus J: Current disease-modifying treatment of multiple sclerosis. *Mt Sinai J Med* 2011;78:161–175.
- 25 Wingerchuk DM, Noseworthy JH: Randomized controlled trials to assess therapies for multiple sclerosis. *Neurology* 2002;58(suppl 4):S40–S48.
- 26 Benson K, Hartz AJ: A comparison of observational studies and randomized, controlled trials. *N Engl J Med* 2000;342:1878–1886.